NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…
Senate health committee advances changes to how FDA would approve new opioids
The Senate Health, Education, Labor and Pensions committee on Tuesday afternoon advanced three major bills related to the opioid epidemic and cancer screening, including an